-
-
-
-
-
-
-
AstraZeneca IMFINZI combo cuts liver cancer progression risk by 30%
-
-
-
-
-
-
-
AstraZeneca's BAXFENDY wins FDA approval for resistant hypertension
-
-
-
-
-
-
-
AstraZeneca (AZN) Tops Q1 EPS by 6c; offers guidance
-
-
-
-
-
-
-
AstraZeneca (AZN) PT Raised to $220 at Morgan Stanley
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on AstraZeneca (AZN) Amid Potential 'Multi-Billion $ Opportunity'
-
-
-
-
-
-
-
ENHERTU receives priority review for HER2-positive early breast cancer
-
-
-
-
-
-
-
AstraZeneca awards $3.4 million to nonprofits for health equity programs
-
415,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

